Beijing Fengtai Hospital

Abstract Angular velocity is a critical parameter for satellites during on-orbit operation. Current gyro-free angular velocity estimation methods based on star sensors predominantly rely on multiple frames of star images and are effective under relatively small maneuvers of the star sensor. This paper proposes an angular velocity estimation approach utilizing single-frame star image data captured by a high-dynamic star sensor operating under rolling shutter exposure mode. By analyzing the motion patterns of star points in single-frame images, an angular velocity estimation optimization model was established with inter-star angular distances as the objective function. Accurate angular velocity estimation was achieved through the simulated annealing algorithm. To evaluate the star sensor's performance under high-dynamic conditions, three representative operational working conditions were simulated numerically. Experimental results demonstrate: under composite motion with dual-axis angular velocity of 15°/s and angular acceleration of 0.8°/s², the root mean square errors (RMSE) for triaxial angular velocity estimation are 0.0378°/s (X-axis), 0.0365°/s (Y-axis), and 0.1947°/s (Z-axis). Notably, when subjected to sinusoidal/cosinusoidal dynamic angular velocity excitation with amplitude of 15°/s, the maximum comprehensive error of triaxial angular velocity estimation does not exceed 0.103°/s, validating the algorithm's robustness in complex motion environments.

Overactive bladder (OAB) is characterized by urinary urgency, often accompanied by increased frequency and nocturia, and is associated with impaired quality of life and substantial healthcare burden. Although ketogenic dietary patterns have been linked to weight reduction, decreased systemic inflammation, and improved metabolic profiles, their relationship with OAB remains unclear. This study aimed to examine the association between the dietary ketogenic ratio (DKR) and OAB, and to explore the potential mediating roles of the Weight-adjusted-waist index (WWI) and the Dietary Inflammatory Index (DII). Data were derived from 23,763 participants in the 2009-2018 National Health and Nutrition Examination Survey (NHANES), including 4991 individuals reporting OAB. Dietary intake was assessed using two 24-h dietary recalls. DKR, DII, and WWI were calculated using validated approaches. Multivariable logistic regression, subgroup analyses, and smoothed curve fitting were performed to evaluate the association between DKR and OAB, and mediation analyses were conducted to assess indirect effects. Each unit increase in DII was associated with 11% higher odds of OAB (OR = 1.11, 95% CI: 1.06-1.16), whereas each unit increase in DKR was associated with 43% lower odds of OAB (OR = 0.57, 95% CI: 0.42-0.77). Compared with the lowest quartile, participants in the highest quartile of DKR had a significantly lower prevalence of OAB. Mediation analyses suggested that DII and WWI accounted for 8.29% and 6.57% of the association between DKR and OAB, respectively. Higher DKR was associated with a lower prevalence of OAB, and this relationship was partially mediated by dietary inflammatory potential and central adiposity. These findings highlight the potential relevance of dietary patterns in OAB prevention and warrant further prospective investigation.

Inactivating vascular endothelial growth factor receptor (VEGFR) may improve the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC). The ATTENTION study (phase II, open-label, randomized, multicenter trial (Registration number: ChiCTR2100047453), evaluated the efficacy and safety of aumolertinib plus apatinib vs. aumolertinib alone in untreated, EGFR-mutant, advanced NSCLC. The primary endpoint was the 18-month PFS rate. Across 18 centers in China, 104 patients were enrolled to receive aumolertinib alone (n = 51) or with apatinib (n = 53). At a median follow-up duration of 19.4 months, aumolertinib plus apatinib outperformed aumolertinib alone in terms of the 18-month progression-free survival (PFS) rate (74% vs. 50%, P = 0.036), median PFS (not reached [NR] vs. 20.1 months, hazard ratio [HR] = 0.41, P = 0.017), and objective response rate (79% vs. 59%, P = 0.024). No grade 4/5 treatment-related adverse effects (TRAEs) were observed, whereas grade 3 TRAEs occurred in 38% vs. 27% of patients, with hypertension (11%) and platelet count decrease (9%) being most common in the combination arm. Exploratory analysis revealed that PFS benefits from aumolertinib plus apatinib predominantly in those with TP53 mutations. As an infusion-free option, aumolertinib plus apatinib demonstrated PFS benefits with manageable safety in patients with untreated, EGFR-mutant, advanced NSCLC.

This study aimed to characterize the non-central nervous system extramedullary disease (non-CNS EMD) in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) and to evaluate the prognostic value of metabolic parameters derived from [18F]FDG PET/CT imaging. Patients with r/r B-ALL who received chimeric antigen receptor (CAR)-T cell therapy and underwent [18F]FDG PET/CT before CAR-T cell therapy were retrospectively enrolled. Lesions were semi-automatically segmented using LIFEx software, based on a threshold of 41% of the maximal uptake value. The anatomical locations of FDG-avid lesions were summarized to delineate the characteristics of non-CNS EMD. Furthermore, metabolic parameters from FDG PET/CT (SUVmax, MTV, and TLG) as well as selected clinical and laboratory features were collected. These variables were categorized into two groups for survival analysis. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. A total of 81 B-ALL patients were included in this study. The most frequently observed non-CNS EMD lesions involved the lymph node, spleen, and kidney. After a median follow-up time of 23.7 months, multivariate analysis identified hemoglobin (Hb) and SUVmax (with a cut-off value of 7.0) as independent prognostic factors for PFS and OS. Patients with abnormal Hb levels exhibited significantly shorter PFS and OS compared to those with normal Hb levels (median PFS: 13.5 months vs. not reached, P = 0.004; median OS: 48.0 months vs. not reached, P = 0.010). Similarly, patients with SUVmax above the threshold had significantly reduced PFS and OS compared to those below the threshold (median PFS: 9.1 months vs. not reached, P ≤ 0.001; median OS: 27.0 months vs. 50.8 months, P = 0.020). [18F]FDG PET/CT effectively visualizes extramedullary infiltration in patients with B-ALL, and these non-CNS EMD lesions were also associated with clinical outcomes. SUVmax serves as a valuable predictive biomarker for both PFS and OS.

To evaluate the clinical efficacy of laparoscopic common bile duct exploration (LCBDE) combined with choledochoscopy and primary closure without T-tube drainage in managing acute abdominal pain caused by choledocholithiasis (common bile duct stones, CBDS) and cholecystolithiasis with acute cholecystitis. A single-center prospective study was conducted at the Department of General Surgery, Beijing Fengtai Youanmen Hospital, from April 2024 to February 2025. Sixty-one patients with acute abdominal pain due to CBDS and cholecystolithiasis with acute cholecystitis were randomized into two groups: T-tube-free group (n = 35), Triple-port laparoscopic cholecystectomy (LC) + LCBDE with primary closure; T-tube group (n = 26), Four-port LC + LCBDE with T-tube drainage. Perioperative outcomes were compared between the groups. Baseline characteristics were comparable (all P > 0.05). The T-tube-free group demonstrated superior outcomes in operative time, intraoperative blood loss, postoperative pain, duration of abdominal drainage, and hospital stay (all P < 0.05). Each group had one case of biliary leakage, both resolved conservatively. No mortality, pancreatitis, conversion to open surgery, residual stones, biliary hemorrhage, or strictures occurred in either group. Triple-port LC combined with LCBDE and primary closure without T-tube drainage is safe and feasible for acute abdominal pain. Compared to T-tube drainage, this approach better aligns with the principles of enhanced recovery after surgery (ERAS).

BackgroundPerioperative sleep disorders (PSDs) in elderly patients under general anesthesia are associated with high morbidity and severely affect patients’ prognosis. In recent years, vagus nerve electrical stimulation (VNS) has been shown to treat diseases related to autonomic dysfunction, and its anti-inflammatory and other mechanisms may present potential therapeutic possibilities for sleep disorders. This study aimed to investigate the efficacy of transauricular vagal nerve stimulation in improving sleep disorders in elderly patients.Methods/designThis is a single-center, prospective, randomized, controlled clinical trial. A total of 164 elderly patients receiving general anesthesia were randomized at a 1:1 ratio into two groups: one receiving electrical vagus nerve stimulation during the perioperative period and the other receiving sham stimulation. The primary outcome was the incidence of perioperative sleep disorders within 3 days postoperatively, which was defined as an Athens Insomnia Scale (AIS) score of ≥ 6 or a numerical rating scale (NRS) score of ≥ 6. Further effectiveness and safety parameters included sleep quality on days 1, 3, and 5 after surgery, the postoperative pain score, the hospital anxiety‒depression score, the incidence of postoperative delirium, and the incidence of related adverse events.DiscussionThis study aimed to investigate the efficacy and feasibility of using taVNS to improve PSD in elderly patients receiving general anesthesia.Trial registration numberClinicalTrials.gov NCT06421051. Registered on May 10, 2024.Protocol Version: 1.0Date: 2024–05-01.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13063-026-09459-z.